Skip to main content
. Author manuscript; available in PMC: 2013 Aug 12.
Published in final edited form as: J Urol. 2012 Nov 7;189(4):1421–1426. doi: 10.1016/j.juro.2012.11.003

Table 2.

Changes from baseline of other efficacy end points for EE population

Mean ± SD
Vehicle
Mean ± SD
PRX302
p Value* (ANCOVA)
QoL score (possible range 0–6):
 Mo 3 −1.0 ± 1.4 −1.4 ± 1.4 0.392
 Mo 12 −1.0 ± 1.6 −1.2 ± 1.3 0.271
% Voided vol (ml):
 Mo 3 5.4 ± 15.8 0.8 ± 16.0 0.827
 Mo 12 2.0 ± 19.5 −0.7 ± 16.0 0.729
PVR (ml):
 Mo 3 −0.7 ± 86.7 3.6 ± 62.9 0.424
 Mo 12 5.3 ± 87.4 12.2 ± 60.6 0.443
PV (gm):
 Mo 3 −9.5 ± 9.6 −6.1 ± 8.4 0.298
 Mo 6 (no mo 12 assessment) −4.4 ± 10.0 −2.2 ± 9.4 0.440